BiotechTube
Altogen Labs

Altogen Labs

Austin, United States· Est.
altogenlabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14.5M

Overview

Founded in 2009, Altogen Labs is a privately held preclinical CRO providing essential research services to accelerate oncology and therapeutic development. Its key offerings include over 100 validated CDX and PDX xenograft models, rapid 28-day stable cell line generation, and end-to-end RNAi services featuring tissue-targeted in vivo delivery. The company operates as a fee-for-service laboratory, generating revenue by supporting client projects from study design through regulatory submissions, while clients retain all intellectual property.

Oncology

Technology Platform

Integrated preclinical CRO service platforms including validated xenograft models (CDX/PDX), end-to-end RNAi services (design to in vivo targeted delivery), rapid stable cell line development, and liposome encapsulation for various payloads.

Funding History

2
Total raised:$14.5M
Series A$12M
Seed$2.5M

Opportunities

Growth is fueled by increasing outsourcing in biopharma R&D and the rapid expansion of the RNA therapeutics market, which creates high demand for specialized in vivo delivery and analysis services.
The need for more predictive preclinical models, such as PDX, presents a specific niche where Altogen can leverage its validated library.

Risk Factors

Revenue is susceptible to fluctuations in client R&D budgets and economic cycles.
The company faces intense competition from both large global CROs and niche specialists.
Operational risks include the need to maintain stringent GLP compliance and data integrity across all studies.

Competitive Landscape

Altogen Labs competes in the fragmented preclinical CRO market against large players like Charles River Laboratories and LabCorp's preclinical segment, as well as numerous smaller, specialized labs. Its differentiation hinges on its integrated service offering, particularly its emphasized expertise in in vivo RNAi delivery and its large bank of validated xenograft models.

More companies in Oncology (General) →More companies in United States →